Doptelet belongs to a group of medicines called thrombopoietin receptor agonists (TPO-RAs). These work by mimicking a natural protein that helps the body make more platelets. This approval is important because it offers a pill-based option and does not require injections. Doptelet can be taken with food and doesn’t require any special diet changes.
There is no permanent cure for ITP, and symptoms can return even after treatment. Having more options like Doptelet may help doctors better manage this condition in children who need long-term care.
Why Was It Approved?
Doptelet was approved because studies showed it helped raise platelet counts in both children and adults with chronic ITP and in adults with liver disease who needed a procedure.
Doptelet was studied in 75 children with ITP who had not improved with earlier treatments. The children were randomly selected to receive either Doptelet or a placebo. Among those taking Doptelet, about 28% reached a stable platelet count without needing additional treatment, and 81% showed improved platelet levels. By the eighth day of treatment, more than half of the children had platelet levels above the target range. In contrast, none of the children receiving the placebo showed similar improvements at any point during the study.
The most common side effects reported during the study were mild and included viral infections, cough, sore throat, and fever. Serious side effects are rare, and no deaths or major bleeding events were reported during the studies.
What Do I Need to Know?
Doptelet is taken by mouth as a tablet (for children 6 or older) or as a sprinkle (for younger children) with food. The sprinkle form comes in a capsule that can be opened and mixed with soft food or liquid to make swallowing easier. But the granules should not be crushed or chewed.
If your child has ITP and hasn’t improved with other treatments, Doptelet might be an option.
